---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006881"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T01:01:59.254277+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q3 ORLADEYO rev $159.1M (+37%); raises FY guidance; agrees to acquire Astria

## Summary
- ORLADEYO net rev Q3 $159.1M (+37% yoy); total rev $159.4M (+36%); non-GAAP op profit $51.7M (+107%).
- Net income $12.9M ($0.06) vs net loss $14.0M ($0.07 loss) prior year; non-GAAP net income $35.6M ($0.17).
- FY 2025 ORLADEYO rev guidance raised to $590-600M; non-GAAP op expense lowered to $430-440M; on track for positive cash flow.
- Sale of European ORLADEYO business closed; proceeds used to retire remaining $198.7M Pharmakon term debt; pro forma cash $294M.
- Definitive agreement to acquire Astria Therapeutics (navenibart Phase 3 HAE); expected close Q1 2026; Ron Dullinger named CCO effective Jan 1, 2026.

## SEC filing metadata
- accession: 0001171843-25-006881
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/0001171843-25-006881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/f8k_110325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006881
- JSON: https://secwatch.observer/filing/0001171843-25-006881.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.